FEMTOBIOMED Inc. is a next-generation biotechnology company leading innovation in non-viral cell engineering and gene delivery technologies. Since its founding in 2011, FEMTOBIOMED has focused on overcoming the critical challenges in cell and gene therapy manufacturing, with a vision to simplify complex bioprocesses while improving safety, scalability, and therapeutic performance.

At the core of FEMTOBIOMED’s innovation is the CellShot® platform — a proprietary Partitioned Flow Electroporation (PFEP™) technology that represents a paradigm shift in the field of electroporation. Unlike conventional methods, CellShot® PFEP™ physically separates cells from genetic materials during transfection, eliminating the need for cytotoxic buffers, cell washing steps, or mixing processes. This enables highly efficient and gentle delivery of mRNA, CRISPR, and other gene editing tools directly in standard culture media, with exceptional cell viability and transfection performance.

In 2024, FEMTOBIOMED’s CellShot® Badger system achieved U.S. FDA Drug Master File registration (MF #30803), validating its readiness for cGMP manufacturing of advanced cell therapies.

With its platform already recognized by leading academic and clinical partners, including Johns Hopkins University, FEMTOBIOMED is expanding its global footprint through collaborative R&D and strategic OEM partnerships.

Driven by a commitment to technical excellence and patient-centered innovation, FEMTOBIOMED empowers the next wave of cell and gene therapy development — enabling safer, faster, and more scalable manufacturing solutions for the future of regenerative medicine.